480 related articles for article (PubMed ID: 25825203)
1. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
[TBL] [Abstract][Full Text] [Related]
2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate induces cell apoptosis in chronic myeloid leukaemia by regulating Bcr/Abl-mediated p38-MAPK/JNK and JAK2/STAT3/AKT signalling pathways.
Xiao X; Jiang K; Xu Y; Peng H; Wang Z; Liu S; Zhang G
Clin Exp Pharmacol Physiol; 2019 Feb; 46(2):126-136. PubMed ID: 30251267
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Goker B; Caliskan C; Onur Caglar H; Kayabasi C; Balci T; Erbaykent Tepedelen B; Aygunes D; Yilmaz Susluer S; Mutlu Z; Selvi Gunel N; Korkmaz M; Saydam G; Gunduz C; Biray Avci C
J BUON; 2014; 19(4):992-8. PubMed ID: 25536607
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of HDAC3 and STAT3 is critically involved in 1-stearoyl-sn-glycero-3-phosphocholine-induced apoptosis in chronic myelogenous leukemia K562 cells.
Jung JH; Jeong SJ; Kim JH; Jung SK; Jung DB; Lee D; Sohn EJ; Yun M; Lee HJ; Lee HJ; Kim SH
Cell Biochem Biophys; 2013; 67(3):1379-89. PubMed ID: 23729004
[TBL] [Abstract][Full Text] [Related]
7. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
9. An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
Xia Y; Feng M; Wang E; Chen L; Wang J; Hou R; Zhao Y
Chem Biodivers; 2019 Oct; 16(10):e1900443. PubMed ID: 31468670
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
11. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
12. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
13. A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells.
Wang F; Wang J; Chong Z; Mu Y
Anticancer Drugs; 2019 Feb; 30(2):159-166. PubMed ID: 30422832
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
Al-Rawashde FA; Wan Taib WR; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3959-3965. PubMed ID: 34967577
[TBL] [Abstract][Full Text] [Related]
19. Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Cheng R; Huang Y; Fang Y; Wang Q; Yan M; Ge Y
Pharm Biol; 2021 Dec; 59(1):893-903. PubMed ID: 34214017
[TBL] [Abstract][Full Text] [Related]
20. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Trécul A; Morceau F; Gaigneaux A; Orsini M; Chateauvieux S; Grandjenette C; Dicato M; Diederich M
Cancer Lett; 2013 Oct; 340(1):30-42. PubMed ID: 23811288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]